AstraZeneca's Farxiga heart failure drug gets extended US approval

AstraZeneca's Farxiga drug has been approved in the US to reduce the risk of cardiovascular death, hospitalisation for heart failure and urgent heart failure visits in adults, the company said on Tuesday.

The approval by the Food and Drug Administration was based on positive results from the DELIVER Phase III trial.1 Farxiga was previously approved in the US for adults with heart failure with reduced ejection fraction.

Reporting by Frank Prenesti for Sharecast.com